---
title: Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
date: '2024-02-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38393328/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240224170829&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Benralizumab was noninferior to mepolizumab for the induction
  of remission in patients with relapsing or refractory EGPA. (Funded by AstraZeneca;
  MANDARA ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Benralizumab was noninferior to mepolizumab for the induction of remission in patients with relapsing or refractory EGPA. (Funded by AstraZeneca; MANDARA ClinicalTrials.gov number, ...